Your browser doesn't support javascript.
loading
The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.
Moyo, Tamara K; Mendler, Jason H; Itzykson, Raphael; Kishtagari, Ashwin; Solary, Eric; Seegmiller, Adam C; Gerds, Aaron T; Ayers, Gregory D; Dezern, Amy E; Nazha, Aziz; Valent, Peter; van de Loosdrecht, Arjan A; Onida, Francesco; Pleyer, Lisa; Cirici, Blanca Xicoy; Tibes, Raoul; Geissler, Klaus; Komrokji, Rami S; Zhang, Jing; Germing, Ulrich; Steensma, David P; Wiseman, Daniel H; Pfeilstöecker, Michael; Elena, Chiara; Cross, Nicholas C P; Kiladjian, Jean-Jacques; Luebbert, Michael; Mesa, Ruben A; Montalban-Bravo, Guillermo; Sanz, Guillermo F; Platzbecker, Uwe; Patnaik, Mrinal M; Padron, Eric; Santini, Valeria; Fenaux, Pierre; Savona, Michael R.
Afiliação
  • Moyo TK; Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, 2220 Pierce Avenue, Nashville, TN, 777 PRB, USA.
  • Mendler JH; Levine Cancer Institute, Charlotte, NC, USA.
  • Itzykson R; James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
  • Kishtagari A; Paris Diderot University, Paris, France.
  • Solary E; Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, 2220 Pierce Avenue, Nashville, TN, 777 PRB, USA.
  • Seegmiller AC; Institut Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Gerds AT; Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, 2220 Pierce Avenue, Nashville, TN, 777 PRB, USA.
  • Ayers GD; Cleveland Clinic, Cleveland, OH, USA.
  • Dezern AE; Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, 2220 Pierce Avenue, Nashville, TN, 777 PRB, USA.
  • Nazha A; Johns Hopkins University, Baltimore, MD, USA.
  • Valent P; Cleveland Clinic, Cleveland, OH, USA.
  • van de Loosdrecht AA; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
  • Onida F; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
  • Pleyer L; VU University Medical Center, Amsterdam, Netherlands.
  • Cirici BX; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
  • Tibes R; Third Medical Department With Hematology, Medical Oncology, Rheumatology and Infectiology, Paracelsus Medical University, Salzburg, Austria.
  • Geissler K; Salzburg Cancer Research Institute Center for Clinical Cancer and Immunology Trials, Salzburg, Austria.
  • Komrokji RS; Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Bellaterr, Spain.
  • Zhang J; Mayo Clinic, Scottsdale, AZ, USA.
  • Germing U; Sigmund Freud University, Vienna, Austria.
  • Steensma DP; H. Lee Moffitt Cancer Center, Tampa, FL, USA.
  • Wiseman DH; University of Wisconsin-Madison, Madison, WI, USA.
  • Pfeilstöecker M; Department of Hematology, Oncology, and Clinical Immunology, University of Duesseldorf, Duesseldorf, Germany.
  • Elena C; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Cross NCP; University of Manchester, Manchester, UK.
  • Kiladjian JJ; Hanusch Hospital and Ludwig Boltzmann Institute for Hematology and Oncology, Vienna, Austria.
  • Luebbert M; University of Pavia, Pavia, Italy.
  • Mesa RA; School of Medicine, University of Southampton, Southampton, UK.
  • Montalban-Bravo G; Université de Paris, APHP, Hôpital Saint-Louis, Centre d'Investigations Cliniques, INSERM CIC 1427, Paris, France.
  • Sanz GF; University of Freiburg, Freiburg, Germany.
  • Platzbecker U; Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX, USA.
  • Patnaik MM; MD Anderson Cancer Center, Houston, TX, USA.
  • Padron E; Hospital Universitario Y Politécnico La Fe, Valencia, Spain.
  • Santini V; University Hospital Leipzig, Leipzig, Germany.
  • Fenaux P; Mayo Clinic, Rochester, MN, USA.
  • Savona MR; H. Lee Moffitt Cancer Center, Tampa, FL, USA.
BMC Cancer ; 22(1): 1013, 2022 Sep 24.
Article em En | MEDLINE | ID: mdl-36153475
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Doenças Mieloproliferativas-Mielodisplásicas Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Doenças Mieloproliferativas-Mielodisplásicas Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article